Such a high valuation means the potential benefit of the housing recovery is already priced into the stock.

FORBES: Financial Sector Funds And ETFs Need Less Citi, More Discover

In fact, the Cowen analysts say, the last stock to outperform after its FDA launch was Alexion, the maker of the high-priced orphan drug Soliris, in 2007.

FORBES: Biotech, Where Winners Lose

For those investors that can get out of their bunkers to do some stock picking, you might want to go for some high-quality, low-priced dividend stocks that will pay you to own them.

FORBES: It Pays To Own These Three Stocks